- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04232800
Riboflavin for Glutamate Reduction in Alcohol Withdrawal (RGRAW)
Study Overview
Status
Intervention / Treatment
Detailed Description
General Investigational Plan
Hypotheses:
Aim 1: Measure the impact of daily oral riboflavin supplementation on blood Glu levels.
Hypothesis 1: Patients receiving riboflavin will have significant reductions in blood Glu levels, as compared to placebo.
- Aim 2: Observe the impact of oral riboflavin on CIWA-AR scale scoring. Hypothesis 2: Riboflavin will significantly reduce the active group's CIWA-AR scores, and will result in fewer symptom triggered benzodiazepine doses, as compared to placebo.
Plan: The proposed study would apply a recently identified method using vitamin B2 (riboflavin) to reduce excess brain Glu activity in veterans in acute alcohol withdrawal. This method of "glutamate scavenging", was identified in a 2018 as a way to reduce glutamate associated brain damage which typically occurs after stroke. When tested in human patients immediately following stroke, the intervention demonstrated efficacy through better structural and functional outcomes when compared to placebo. Improvements persisted at 3 months after the initial stroke, and were not associated with any known side effects. Administration of riboflavin quickly decreases Glu levels in both the blood and brain, as measured using chromatography and Magnetic Resonance Imaging (MRI), respectively. As riboflavin's Glu reducing properties have just been discovered, this method has only been applied to the treatment of stroke, and has yet to be studied outside of the field of neurology. Further, oral riboflavin has not been investigated as a method of glutamate reduction. The hyperglutamatergic state in patients with alcohol withdrawal provides one opportunity for such an investigation, one that may lead to future studies improving treatments of alcohol withdrawal. Chronic, as well as acute alcohol users have both elevated extracellular glutamate as well as changes to glutamate receptors and transporters. These changes appear play a role in the rewarding effects of alcohol, and contribute to the symptoms of withdrawal. A positive correlation exists between CSF levels of glutamate and the severity of alcohol dependence, and patients in acute withdrawal have measurably increased levels of glutamate in their peripheral blood. During early withdrawal, elevated glutamate levels have been observed in the hippocampus and anterior cingulate cortex, returning to normal 3 days after symptom resolution. Given this information, riboflavin may provide a safe, effective, and affordable intervention to normalize the hyperglutamatergic state associated with alcohol withdrawal. The proposed study would investigate this hypothesis in patients admitted to the inpatient psychiatry unit in acute alcohol withdrawal.
Methods: Participants would be recruited on the inpatient psychiatry unit as they were admitted. The primary teams/on call residents would be asked to page a study member if a patient was admitted on the standard protocol for alcohol withdrawal: the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar). The study coordinator would consent the patient, and they would be randomized to either the placebo or riboflavin group. They would then receive TID oral dosing of either 100mg riboflavin or placebo, in addition to treatment as usual. The primary outcome would be daily blood glutamate levels, obtained with the normal morning labs. Secondary outcomes would CIWA scores, number of symptom-triggered benzodiazepines given, anxiety, and alcohol craving scores (using standardized measures).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Andrew J Hughes, MD
- Phone Number: 7014711543
- Email: andrew.j.hughes.1@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult veterans ages 18-65
- Admitted to the inpatient psychiatric unit at the Portland VA
- Determine by admitting physician to be currently in or at risk of alcohol withdrawal during admission
- Placed on the CIWA-AR protocol
- Willing to provide informed consent/HIPAA authorization and accept randomization
- Willing to ingest three capsules/day
- Willing to provide daily blood samples H) Fluent in English
Exclusion Criteria:
- Known allergy to ingredients of riboflavin, capsules, or placebo ingredients
- Taking any medication acting primarily on Glu receptors (e.g. memantine) or GABA receptors (benzodiazepines) at baseline
- Unable to swallow capsules
- Actively in withdrawal from substances other than alcohol
- Unable to provide full informed consent/HIPAA authorization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Riboflavin
Participants in this group will receive 100mg riboflavin TID during study participation.
|
The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
Other Names:
|
Placebo Comparator: Placebo
Participants in this group will receive inert placebo capsules TID during study participation.
|
An inert, standard placebo in identical capsules to primary intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral blood glutamate level at baseline
Time Frame: Will occur on the day of enrollment in the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on the day of enrollment in the study
|
Peripheral blood glutamate level, day 2
Time Frame: Will occur on day 2 of the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on day 2 of the study
|
Peripheral blood glutamate level, day 4
Time Frame: Will occur on day 4 of the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on day 4 of the study
|
Peripheral blood glutamate level, day 6
Time Frame: Will occur on day 6 of the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on day 6 of the study
|
Peripheral blood glutamate level, day 8
Time Frame: Will occur on day 8 of the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on day 8 of the study
|
Peripheral blood glutamate level, day 10
Time Frame: Will occur on day 10 of the study
|
measured using high performance liquid chromatography (HPLC)
|
Will occur on day 10 of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day of enrollment in the study
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day of enrollment in the study
|
Day 2: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
Day 3: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
Day 4: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
Day 5: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
Day 6: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
Day 7: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
Day 8: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
Day 9: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
Day 10: Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale scores
Time Frame: Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
The CIWA-Ar scale is a measure used in standard of care treatment of alcohol withdrawal.
It assesses severity of symptoms, and can be used to determine the need for supportive therapy (e.g.
benzodiazepines).It will be collected as standard of care, and will be analyzed as a secondary outcome measure.Scores range from 0-67, with a higher number indicating increased symptoms of alcohol withdrawal.
|
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
Baseline: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day of enrollment in the study
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day of enrollment in the study
|
Day 2: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
Day 3: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
Day 4: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
Day 5: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
Day 6: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
Day 7: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
Day 8: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
Day 9: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
Day 10: # of Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale triggered benzodiazepine administration
Time Frame: Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
As part of standard of care for acute alcohol withdrawal, patients are administered benzodiazepines for symptoms if a clinician-determined threshold is met.
That is, patients who are more symptomatic (higher CIWA-Ar) scores, receive more benzodiazepines.
This data is collected as standard of care, but will be used as a secondary outcome for this study.
|
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
Baseline: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day of enrollment in the study
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day of enrollment in the study
|
Day 2: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
Day 3: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
Day 4: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
Day 5: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
Day 6: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
Day 7: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
Day 8: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
Day 9: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
Day 10: Generalized Anxiety Disorder - 7 (GAD7) scale
Time Frame: Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
A standardized measure of anxiety over the previous 2 weeks.
Scores range from 0-21, with a higher score indicating more symptoms of anxiety.
|
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
Baseline: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day of enrollment in the study
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day of enrollment in the study
|
Day 2: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
Day 3: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
Day 4: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
Day 5: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
Day 6: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
Day 7: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
Day 8: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
Day 9: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
Day 10: The Alcohol Craving Questionnaire-Revised (ACQ-R)
Time Frame: Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
A brief, reliable, and validated measure of alcohol craving.
Scores range from 1-7 with higher scores indicating stronger alcohol cravings
|
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
Baseline: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day of enrollment in the study
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day of enrollment in the study
|
Day 2: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 2 after randomization (if participant has not yet discharged from the hospital)
|
Day 3: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 3 after randomization (if participant has not yet discharged from the hospital)
|
Day 4: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 4 after randomization (if participant has not yet discharged from the hospital)
|
Day 5: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 5 after randomization (if participant has not yet discharged from the hospital)
|
Day 6: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 6 after randomization (if participant has not yet discharged from the hospital)
|
Day 7: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 7 after randomization (if participant has not yet discharged from the hospital)
|
Day 8: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 8 after randomization (if participant has not yet discharged from the hospital)
|
Day 9: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 9 after randomization (if participant has not yet discharged from the hospital)
|
Day 10: The Daily Assessment of Symptoms -Anxiety (DAS-A)
Time Frame: Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
A reliable and valid measure of anxiety which has been shown to detect reduction of anxiety symptoms within 24 hours.
Scores range from 0-80, with a higher score indicating more symptoms of anxiety
|
Will occur on the day 10 after randomization (if participant has not yet discharged from the hospital)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Brandon Cornejo, MD, PhD, Oregon Health & Science University, Portland Veterans Health Administration
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGRAW
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nutrition Disorders
-
NestléCompletedNutrition Disorder, ChildUnited Kingdom
-
Harran UniversityRecruitingNutrition | Nutrition Disorder, InfantTurkey
-
Universidad de MonterreyFEMSA Foundation; Mexican Food BanksCompletedMalnutrition | Malnutrition, Child | Malnutrition in Children | Child Malnutrition | Child Overnutrition | Nutrition Disorders, ChildMexico
-
Jimma UniversityUnknown
-
Danone Early Life Nutrition BrazilUniversidade Federal do Rio Grande do Norte; Federal University of Health Science... and other collaboratorsCompletedChild Nutrition Disorders
-
Lata Medical Research Foundation, NagpurNational Health and Medical Research Council, Australia; Dimagi Inc.; ADVANCING...Unknown
-
Augusta UniversityActive, not recruiting
-
FHI 360United States Agency for International Development (USAID); UNICEF; Ministry...TerminatedBreast Feeding | Nutrition | Child MalnutritionAfghanistan
-
Nemours Children's ClinicChildren's Hospital Medical Center, CincinnatiNot yet recruitingBody Composition | Feeding; Difficult, Newborn | Nutrition Disorder, InfantUnited States
-
NestléWithdrawnEnteral Feeding Intolerance | Tube Feeding | Nutrition Disorder, ChildUnited States
Clinical Trials on Riboflavin
-
Instituto de Oftalmología Fundación Conde de ValencianaUnknownKeratoconus | CrosslinkingMexico
-
Price Vision GroupRecruitingKeratoconus | Ectasia CornealUnited States
-
University of UlsterDSM Nutritional Products, Inc.Enrolling by invitationHypertension | Blood PressureUnited Kingdom
-
Cornea and Laser Eye InstituteActive, not recruitingKeratoconus | Corneal EctasiaUnited States
-
DSM Nutritional Products, Inc.CompletedGut MicrobiotaNetherlands
-
Glaukos CorporationWithdrawn
-
Price Vision GroupCornea Research Foundation of AmericaRecruitingCorneal NeovascularizationUnited States
-
Region SkaneActive, not recruiting
-
Cornea and Laser Eye InstituteActive, not recruitingKeratoconus | Corneal EctasiaUnited States
-
University of UlsterDSM Nutritional Products, Inc.UnknownParticipants With the MTHFR 677TT GenotypeUnited Kingdom